Protalix BioTherapeutics (PLX) Liabilities and Shareholders Equity (2010 - 2026)

Protalix BioTherapeutics has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $102.3 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 38.49% year-over-year to $102.3 million; the trailing twelve-month figure through Mar 2026 stood at $345.4 million (up 14.99% YoY), and the FY2025 full-year result was $82.3 million, up 12.16% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $102.3 million, up from $82.3 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $102.3 million in Q1 2026, with the low at $55.8 million in Q4 2022.
• Average Liabilities and Shareholders Equity over 5 years is $76.7 million, with a median of $78.5 million recorded in 2025.
• Year-over-year, Liabilities and Shareholders Equity sank 43.96% in 2022 and surged 54.42% in 2023.
• Tracing PLX's Liabilities and Shareholders Equity over 5 years: stood at $55.8 million in 2022, then jumped by 51.35% to $84.4 million in 2023, then retreated by 13.05% to $73.4 million in 2024, then rose by 12.16% to $82.3 million in 2025, then increased by 24.28% to $102.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $102.3 million (Q1 2026), $82.3 million (Q4 2025), and $82.3 million (Q3 2025), per Business Quant data.

Peer Comparison